Medtechs Must Gear Up For New China Data Protection Rules
New Controls On Access To Data Underline Global Perceptions That ‘China is for China’
China ambitiously wants to champion domestic medtech manufacturers in the global market. It also needs to ensure foreign manufacturers do not sustainably dominate its home market – while also benefiting from their technical expertise, for the time being at least. Against that backdrop, new Chinese data laws are being eyed by global medtechs with a certain trepidation.
You may also be interested in...
China’s economic might and industrial drive are being felt increasingly in medtech, and the just-released 14th five-year plan will give Chinese manufacturers more support for expansion, both at home and in overseas markets. Should EU and US industries be worried?
The US listing of Chinese artificial intelligence, medical records and patient management system company Linkdoc could be derailed, after China issued new data review requirements tightening the oversight of overseas listings of domestic companies.
The operating environment for medical technology companies becomes more complex, competitive and costly every year. There is no expectation that 2022 will buck that trend, even as the medtech sector prepares for a third year of working under conditions shaped by the COVID-19 pandemic.